In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests, including:

• LUCHM | LiquidHALLMARK ctDNA and ctRNA
  • As an alternative to invasive tissue biopsies to assist in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with a solid tumor.

• KITQ | KIT p.Asp816Val Variant Analysis, Quantitative, Varies
  • Diagnosing systemic mastocytosis.
• NEUD1 | Neuronal Differentiation 1 (NeuroD1), Technical Component only
  • Subclassification of small cell lung carcinoma.
• NAACD | N-Acetylaspartic Acid, Canavan Disease, Random, Urine
  • Diagnosis and monitoring of individuals with Canavan disease.
  • Follow-up quantitation of abnormal organic acid elevations of N-acetylaspartic acid.
• AACYL | Aminoacylase-1 Deficiency, Urine
  • Follow-up quantitation of abnormal organic acid elevations of N-acetylated amino acids, in particular N-acetylalanine, N-acetylglycine, N-acetylmethionine, and N-acetylglutamic acid.
  • Diagnosis of individuals with aminoacylase-1 deficiency.
  • Evaluating patients with neurologic and psychiatric symptoms of unknown etiology.
• CMVLR | Cytomegalovirus (CMV) Molecular Detection, PCR, Lower Respiratory
  • Rapid qualitative detection of cytomegalovirus (CMV) DNA in lower respiratory specimens.
• K818 | Keratin 8 and 18 (KRT8/18), Technical Component only
  • Aiding in the diagnosis of carcinomas.

Visit our test catalog for more information on new or updated tests and testing algorithms.